会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明公开
    • 중추 신경계 질환의 치료를 위한 리구스틸라이드 유도체
    • 用于治疗中枢神经系统疾病的LIGESTILIDE衍生物
    • KR1020090078777A
    • 2009-07-20
    • KR1020097004959
    • 2007-08-10
    • 디에스엠 아이피 어셋츠 비.브이.
    • 드사이쥬앙트안고랄크지크레지나슐러괴데
    • A61K31/343A61P25/24A61P25/22A23L1/30
    • A61K31/343
    • The present invention refers to compounds of the general formula (I) wherein R1 is hydrogen or hydroxy; R2 is butyl or butyryl if R1 is hydroxy, but R2 is butyl if R1 is hydrogen; or R1 and R2 taken together are 1-propylidene or 1-butylidene optionally substituted by hydroxy, methyl, or 3-(alpha,beta-dimethylacryloyloxy); the dotted line is an optional bond; X is an optionally substituted aliphatic C4-residue selected from the group consisting of X1, X2, X3, X4, and X5; wherein X is X2, X3or X5 if the dotted line in formula (I) is absent; and X is Xl, X4 or X5 if the dotted line signifies a bond in formula (I) above; R3 and R4 are, independently from each other, hydrogen or hydroxy; and R5 is hydroxy or butyryl, for use in the treatment of disorders connected to impaired neurotransmission, as well as to dietary and pharmaceutical compositions containing such compounds, and their uses.
    • 本发明涉及通式(I)的化合物,其中R 1是氢或羟基; 如果R 1是羟基,则R 2是丁基或丁酰基,但如果R 1是氢,则R 2是丁基; 或R 1和R 2一起是1-羟基,甲基或3-(α,β-二甲基丙烯酰氧基)任意取代的1-亚丙基或1-亚丁基; 虚线是可选的键; X是选自X 1,X 2,X 3,X 4和X 5的任选取代的脂族C 4残基; 其中如果式(I)中的虚线不存在,X是X 2,X 3或X 5; 如果虚线表示上述式(I)中的键,X为X 1,X 4或X 5; R 3和R 4彼此独立地为氢或羟基; 和R5是羟基或丁酰基,用于治疗与受损的神经传递相关的疾病,以及含有这些化合物的饮食和药物组合物及其用途。
    • 7. 发明公开
    • 노인성 황반 변성의 치료 또는 예방 방법
    • 治疗或预防老年相关性变性的方法
    • KR1020080052657A
    • 2008-06-11
    • KR1020087008390
    • 2006-09-08
    • 디에스엠 아이피 어셋츠 비.브이.
    • 고랄크지크레지나드새지유안토니슈알크볼팡벤딕이고르
    • A61K31/01A61K31/375A61K31/355
    • A61K33/34A61K31/047A61K31/355A61K31/375A61K33/30A61K2300/00
    • A method of treatment and/or prevention of age-related macular degeneration (AMD) wherein, in a first step, the need for treatment or susceptibility to AMD is determined for an individual and, in a second step, a medication comprising lutein and/or zeaxanthin and/or certain antioxidants (or a mixture thereof) is tailored to that individual. The invention also provides a method of determining a substance to be administered to an individual, which individual may be susceptible of having age-related macular degeneration (or an age-related macular degeneration-related disorder) comprising: a) determining the susceptibility of the individual to age-related macular degeneration (usually genetically, by detection of an SNP); and b) on the basis of the determination in a), identifying a substance capable of preventing or treating age-related macular degeneration in that individual. The method may additionally comprise providing (such as administering or communicating) the substance (or its identity) to the individual.
    • 一种治疗和/或预防年龄相关性黄斑变性(AMD)的方法,其中在第一步骤中,对个体确定对AMD的治疗或易感性的需要,并且在第二步骤中,包含叶黄素和/ 或玉米黄质和/或某些抗氧化剂(或其混合物)适合该个体。 本发明还提供了确定待给予个体的物质的方法,该个体可能易患有年龄相关性黄斑变性(或年龄相关性黄斑变性相关病症),其包括:a)确定 个体对年龄相关性黄斑变性(通常在遗传上,通过检测SNP); 和b)基于a)中确定的物质,鉴定能够预防或治疗该个体年龄相关性黄斑变性的物质。 该方法可以另外包括向个体提供(例如管理或通信)物质(或其身份)。
    • 8. 发明公开
    • 유기 화합물의 신규 용도
    • 有机化合物的新用途
    • KR1020080031012A
    • 2008-04-07
    • KR1020087001079
    • 2006-07-13
    • 디에스엠 아이피 어셋츠 비.브이.
    • 고랄크지크레지나베르츠카린
    • A23L1/30A61K31/01A61K31/045A61K31/07
    • A61K8/34A23K20/111A23K20/174A23K20/179A23L2/58A23L7/126A23L33/105A23V2002/00A61K8/31A61K8/345A61K8/355A61K31/01A61K31/045A61K31/07A61K31/122A61Q19/08A23V2200/318A23V2250/211A23V2250/314A23V2250/712
    • The present invention is directed to the use of a compound selected from the group consisting of beta-carotene, lutein, lycopene and beta-cryptoxanthin, and mixtures thereof and combinations thereof with CoQ-I O for maintaining the energy metabolism, the energy flow and/or the energy production in skin or of skin of animals including humans, for maintaining the respiratory function of the skin of animals including humans, for energizing the skin, maintaining and supporting the radiance and natural glow of the skin of animals including humans and for promoting a healthy appearance of the skin of animals including humans for preventing UV-A radiation-induced mtDNA mutagenesis in skin of animals including humans, as well as for the manufacture of a composition, preferably an orally applicable composition, for these uses and the corresponding methods. The present invention is further directed to the use of a compound selected from the group consisting of beta-carotene, lutein, lycopene and beta-cryptoxanthin, and mixtures thereof and combinations thereof with CoQ-10 in sunscreens as well as daily care products to improve their photoprotective potential, as well as to their use as effective micronutrients for skin maintenance. Furthermore the present invention is directed to compositions, preferably orally applicable compositions, comprising a certain amount of at least one compound selected from the group consisting of beta-carotene, lutein, lycopene and beta-cryptoxanthin and mixtures thereof and combinations thereof with CoQ-10 as active ingredient, characterized in that the amount is effective for such uses as mentioned above.
    • 本发明涉及选自β-胡萝卜素,叶黄素,番茄红素和β-隐黄质及其混合物的化合物及其与CoQ-I O的组合的用途,用于维持能量代谢,能量流和 /或包括人在内的动物的皮肤或皮肤的能量产生,用于维持包括人在内的动物的皮肤的呼吸功能,用于激发皮肤,维持和支持包括人的动物的皮肤的光泽和自然发光,并且为 促进动物包括人类在内的动物皮肤的健康外观,以防止包括人在内的动物的皮肤中的UV-A辐射诱导的mtDNA诱变,以及用于制造用于这些用途的组合物,优选口服适用的组合物 方法。 本发明进一步涉及选自β-胡萝卜素,叶黄素,番茄红素和β-隐黄质及其混合物的化合物及其与CoQ-10在防晒剂中的组合以及日常护理产品的使用的改进 它们的光保护潜力,以及它们作为有效的微量营养素用于皮肤维持。 此外,本发明涉及包含一定量至少一种选自β-胡萝卜素,叶黄素,番茄红素和β-隐黄质及其混合物的组合物,优选口服适用的组合物,以及它们与CoQ-10的组合 作为活性成分,其特征在于该量对于上述用途是有效的。